Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 2/20 | 0.32 |
| ▸ | BRAF | P15056 | 2/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30082704 | 0.89 | SSTR4 (0.38) | POLQHDAC4SSTR4BACE1GRM5 | |
| SCHEMBL30433944 | 0.79 | POLQ (0.35) | POLQHDAC4SSTR4AGBL2BACE1 | |
| SCHEMBL21408257 | 0.79 | POLQ (0.35) | POLQHDAC4SSTR4AGBL2BACE1 | |
| SCHEMBL21408280 | 0.74 | SSTR4 (0.36) | POLQHDAC4SSTR4BACE1GRM5 | |
| SCHEMBL30434411 | 0.73 | POLQ (0.34) | POLQHDAC4SSTR4BACE1GRM5 | |
| SCHEMBL21408269 | 0.73 | POLQ (0.34) | POLQHDAC4SSTR4BACE1GRM5 | |
| SCHEMBL21408267 | 0.72 | PIK3CA (0.35) | POLQBACE1 | |
| SCHEMBL30433680 | 0.72 | PIK3CA (0.35) | POLQBACE1 | |
| SCHEMBL16703963 | 0.71 | POLQ (0.42) | POLQSSTR4AGBL2GRM5GPR6 | |
| SCHEMBL21408268 | 0.69 | RAF1 (0.35) | BACE1RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | FOCHON BIOSCIENCES, LTD. (CN) | 2023-01-17 | — | — | US | disclosed |
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139506-A1 | MACROCYCLIC COMPOUNDS AS TRK KINASES INHIBITORS | PLK2, ERBB3, DMPK | POLQ 1580/4885HDAC4 831/4885SSTR4 1892/4885 |
| US-11555042-B2 | Macrocyclic compounds as TRK kinases inhibitors | PLK2, ERBB3, DMPK | POLQ 1580/4885HDAC4 831/4885SSTR4 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.